The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1/2 dose escalation study of the oral DNA polymerase theta inhibitor (POLQi) GSK4524101 ± niraparib in adults with advanced or metastatic solid tumors.
 
Vivek Samnotra
Employment - GlaxoSmithKline
Leadership - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline; Guardant Health
Travel, Accommodations, Expenses - GlaxoSmithKline
 
Jimmy Belotte
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
 
Veronica Moroz
Employment - GlaxoSmithKline UK Ltd.
Stock and Other Ownership Interests - GlaxoSmithKline
 
Luda Shtessel
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
 
Patrick Hanafin
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
 
Malar Pannirselvam
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
 
Aishwarya Bhaskar
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
Travel, Accommodations, Expenses - GlaxoSmithKline
 
Anu Shilpa Krishnatry
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
 
Debra Rogan
Employment - GlaxoSmithKline
 
Haluk Yuzugullu
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
 
Minal Barve
Employment - Texas Oncology
Stock and Other Ownership Interests - Texas Oncology
Research Funding - SCRI at Mary Crowley Cancer Research
 
Philippe Bedard
Honoraria - Boehringer Ingelheim
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bicara Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); LegoChem Biosciences (Inst); Lilly (Inst); Medicenna (Inst); Merck (Inst); Novartis (Inst); Sanofi (Inst); Seagen (Inst); Takeda (Inst); Zymeworks (Inst)
(OPTIONAL) Uncompensated Relationships - Janssen Oncology; Lilly; Repare Therapeutics; Roche/Genentech; Seagen; Zymeworks
 
Quincy Chu
Honoraria - Abbvie; Amgen; Anheart Therapeutics; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Esperas Pharma; Genprex; GlaxoSmithKline; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Lilly; Merck; Novartis; Ocellaris Pharma; Pfizer; Roche; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Anheart Therapeutics; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Esperas Pharma; Genprex; Genprex; GlaxoSmithKline; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Lilly; Merck; Novartis; Ocellaris Pharma; Pfizer; Roche; Takeda
Other Relationship - GlaxoSmithKline
 
Pamela Munster
Leadership - Alessa Therapeutics
Stock and Other Ownership Interests - Alessa Therapeutics; AtlasMedx; Hap10; OnKure; Parthenon Therapeutics; RasCal
Honoraria - JNJ; Olema Pharmaceuticals; Parthenon Therapeutics
Consulting or Advisory Role - Alessa Therapeutics; AtlasMedx; Olema Pharmaceuticals; RasCal
Research Funding - Actuate Therapeutics (Inst); Amgen (Inst); Arch Oncology (Inst); Arvinas (Inst); Arvinas (Inst); Bliss Biopharmaceutical (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Cyteir; Deciphera (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); IgM Biosciences (Inst); Immune Design (Inst); InventisBio (Inst); Merck (Inst); Novartis (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); PMV Pharma (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Sanofi (Inst); Seagen (Inst); Skorpion (Inst); Tempest Therapeutics (Inst); Xencor (Inst); Xynomic Pharma (Inst)
Patents, Royalties, Other Intellectual Property - UCSF patent on using silastic implants to deliver anticancer agents
Other Relationship - ABIM Subspecialty Board; NIH/NCI
 
Alexander Spira
Leadership - Next Oncology (Inst)
Honoraria - Abbvie; Abbvie; Abbvie; Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Prelude Therapeutics; Takeda
Consulting or Advisory Role - Amgen; ArriVent Biopharma; AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Sanofi; Sanofi; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst)
 
Ramy Saleh
No Relationships to Disclose
 
David Sommerhalder
Employment - Texas Oncology
Stock and Other Ownership Interests - Next Oncology; Texas Oncology/US Oncology
Honoraria - Syneos Health
Consulting or Advisory Role - Nimbus Therapeutics; Revolution Medicines
Research Funding - Abbvie (Inst); Acrivon Therapeutics (Inst); ADC Therapeutics (Inst); Aprea Therapeutics (Inst); Ascentage Pharma (Inst); Astellas Pharma (Inst); Biomea Fusion (Inst); BioNTech SE (Inst); BJ Bioscience (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); Day One Biopharmaceuticals (Inst); Dicerna (Inst); Exelixis (Inst); Fate Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Haihe Pharmaceutical (Inst); IconOVir Bio (Inst); Immuneering (Inst); IMPAC Medical Systems (Inst); Incendia Pharmaceuticals AB (Inst); Kura Oncology (Inst); MediLink (Inst); Mirati Therapeutics (Inst); ModeX Therapeutics (Inst); Monopteros Therapeutics (Inst); Navire (Inst); NGM Biopharmaceuticals (Inst); Nimbus Therapeutics (Inst); Novo Nordisk (Inst); OBI Pharma (Inst); OncoResponse (Inst); Pfizer (Inst); Revolution Medicines (Inst); Step Pharma (Inst); Symphogen (Inst); Tachyon Therapeutics (Inst); Teon Therapeutics (Inst); Tyligand Bioscience (Inst); Vincera Pharma/Vincerx Pharma (Inst); Vividion Therapeutics (Inst); ZielBio (Inst); Zymeworks (Inst)
 
Timothy Yap
Employment - MD Anderson Cancer Center
Stock and Other Ownership Interests - Seagen
Consulting or Advisory Role - 858 Therapeutics; Abbvie; Acrivon Therapeutics; Adagene; Aduro Biotech; Almac Group; Amgen; Amphista Therapeutics; Artios; Astex Pharmaceuticals; AstraZeneca; Athenahealth; Atrin Pharmaceuticals; Avenzo; Avoro Capital Advisors; Axiom Biotechnologies; Baptist Health; Bayer; BeiGene; BioCity Pharma; Bloom Burton; Blueprint Medicines; Boxer; BridGene Biosciences; Bristol-Myers Squibb; C4 Therapeutics; Calithera Biosciences; Cancer Research UK; Carrick Therapeutics; Circle Pharma; Clovis Oncology; Cybrexa Therapeutics; Daiichi Sankyo; Dark Blue Therapeutics; Debiopharm Group; Diffusion Pharmaceuticals; Duke Street Bio; EcoR1 Capital; Ellipses Pharma; EMD Serono; Entos; F-Star; FoRx Therapeutics; Genesis Therapeutics; Genmab; Gerson Lehrman Group; GlaxoSmithKline; Glenmark; Globe Life Science; Grey Wolf Therapeutics; Guidepoint Global; Gustave Roussy Cancer Center; I-Mab; IDEAYA Biosciences; Idience; Ignyta; ImmuneSensor Therapeutics; IMPAC Medical Systems; Intellisphere; Janssen; Joint scientific Committee for Phase I Trials in Hong Kong; Kyn therapeutics; Kyowa Kirin International; Lumanity; MEI Pharma; Merck; Mereo BioPharma; Merit, Inc.; Monte Rosa Therapeutics; Natera; Nested Therapeutics; Nexys Therapeutics; Nimbus Therapeutics; Novocure; Odyssey Therapeutics; OncoSec; Ono Pharmaceutical; Onxeo; Oregon Health & Science University (OHSU); PanAngium Therapeutics; Pegascy; PER; Pfizer; Piper Sandler; Pliant; Prelude Therapeutics; ProLynx; Protai Bio; Radiopharma Theranostics; Repare Therapeutics; resTORbio; Roche; Ryvu Therapeutics; SAKK; Sanofi; Schrodinger; SERVIER; Synnovation; Synthis Therapeutics; Tango Therapeutics; TCG Crossover; TD2; Terns Pharmaceuticals; Terremoto Biosciences; Tessellate Bio; Theragnostics; Thryv Therapeutics; Tolremo; Tome; Trevarx Biomedical; Varian Medical Systems; Veeva; Versant Health; Vibliome Therapeutics; Voronoi Health Analytics; Xinthera; Zai Lab; ZielBio
Research Funding - Acrivon Therapeutics (Inst); Artios (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BioNTech (Inst); Blueprint Medicines (Inst); BMS (Inst); Boundless Bio; Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); CPRIT; Cyteir (Inst); Department of Defense; EMD Serono (Inst); Exelixis; F-Star (Inst); Forbius (Inst); Genentech (Inst); Gilead Sciences; GlaxoSmithKline (Inst); Golfers Against Cancer; Haihe Biopharma (Inst); IDEAYA Biosciences; ImmuneSensor Therapeutics (Inst); InSilico Medicine; Ionis Pharmaceuticals (Inst); Ipsen (Inst); Jounce Therapeutics (Inst); Karyopharm Therapeutics (Inst); KSQ Therapeutics (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); NIH/NCI; Novartis (Inst); Pfizer (Inst); Pliant; Prelude Therapeutics; Regeneron (Inst); Repare Therapeutics (Inst); Ribon Therapeutics (Inst); Roche; Rubius Therapeutics (Inst); Sanofi (Inst); Scholar Rock (Inst); Seagen (Inst); Synnovation; Tango Therapeutics; Tesaro (Inst); V Foundation; Vivace Therapeutics (Inst); Zenith Epigenetics (Inst); Zentalis
 
Brian Van Tine
Leadership - Polaris
Honoraria - Beijing Biostar Pharmaceuticals Co., Ltd.; Oncology Education; Total Health Conference
Consulting or Advisory Role - Aadi; Acuta Capital Partners, LLC; Adaptimmune; Advenchen Laboratories; Boxer Capital LLC; Crisper Therapeutics; Daiihi Sankyo; Deciphera; Galapagos NV; Hinge Bio; Kronos Bio, Inc.; Putnam Associates; Salarius Pharmaceuticals, INc.; Syneos Health
Research Funding - Polaris
Patents, Royalties, Other Intellectual Property - Accuronix Therapeutics- Licensing agreement. Sigma-2 Receptor Ligands and Therapeutic uses therefor (006766), • Modular Platform for Targeted Therapeutic Delivery (006755), • Sigma-2 Receptor Ligand Drug Conjugates as Antitumor Compounds, Methods of synth; Patent on ALEXT3102; Patent on the use of ME1 as a biomarker
Expert Testimony - Health Advances
Travel, Accommodations, Expenses - Adaptimmune; Advenchen Laboratories; Kronos Bio, Inc
 
Michele Sanicola-Nadel
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline